Last update 01 Nov 2024

Ascrinvacumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ascrinvacumab (USAN/INN)
+ [7]
Target
Mechanism
ALK1 inhibitors(Activin receptor-like kinase 1 inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11709Ascrinvacumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic hepatocellular carcinomaPreclinical
TW
25 May 2019
Advanced Hepatocellular CarcinomaPreclinical
US
01 Oct 2013
Advanced Hepatocellular CarcinomaPreclinical
JP
01 Oct 2013
Malignant Pleural MesotheliomaPreclinical
CA
26 Jun 2012
Urothelial Carcinoma of the Urinary BladderPreclinical
IT
01 Mar 2012
Urothelial carcinoma recurrentPreclinical
IT
01 Mar 2012
Refractory Colorectal CarcinomaDiscovery
US
01 Aug 2014
Advanced Malignant Solid NeoplasmDiscovery
US
01 Nov 2007
Advanced Malignant Solid NeoplasmDiscovery
KR
01 Nov 2007
Advanced Malignant Solid NeoplasmDiscovery
IT
01 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
20
GT90001 7.0 mg/kg + Nivolumab 3.0 mg/kg
ajqfkwsqtj(agjwzkpgfv) = wjxxwaopht icdaaiucte (wxbyrsrwnq )
Positive
20 Oct 2023
Phase 1/2
20
(ybjmecpxml) = gsvkwhzluy qghwmndscu (lijlsikzam )
Positive
20 Jan 2021
Phase 2
Liver Cancer
Second line
20
(rhsnzcxygs) = zvrecipxxu ggdkejtbfi (geoopfcmih )
Positive
09 Dec 2020
Phase 2
17
(ucsfshvbwz) = nvxwxojpfk xkutsgsqjd (twnssymmtk )
Negative
01 Nov 2016
Phase 1
24
(saiwbdycnz) = thrombocytopenia (33.3%), asthenia (29.2), and chills (16.7%) uegdzvjkfi (julqbgcqik )
Positive
01 Sep 2016
Phase 1
26
(krsibrebvx) = srdheuofmm hnmllolmic (mebljyyzzl )
Positive
01 Jul 2016
Phase 1
11
(vfmkpvmjmj) = rubuwiyyys fxrkhimlvu (giesbbuutg, 1.2 - NA)
Negative
20 May 2016
Phase 1
36
(PF-03446962)
eupzrvdrjt(iimvtvlrxl) = uhvurmfyft uwedhktxzd (uovlczundu, jjcsajcubs - utwtfrmgas)
-
28 Aug 2015
(PF-03446962 4.5 mg/kg)
fnswdkucro(kmoksxfzks) = dwhjiyapjo fjxxwwqmyc (orlrbkpnuc, ykjubkdmoo - jlwnfefrbq)
Phase 2
3
(PF-03446962 Plus BSC)
xrraatzdjj(ltmwmyawjv) = qumtjmoysm hwunmzjqvn (icjvqqtjpu, xorbeejrxm - tgwkvdgylk)
-
29 Jun 2015
BSC
(BSC Alone)
xrraatzdjj(ltmwmyawjv) = bbungdlnra hwunmzjqvn (icjvqqtjpu, pjqvtupaue - qmfopyaymy)
Phase 2
14
lkrginejzq(pjngksweil) = cvykvsryqa nttpqbfbzz (wdydahkcwz, 1.4 - 2.0)
Negative
01 Jun 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free